A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts.

ABSTRACT:

Background

Nuclear medicine is on the constant search of precision radiopharmaceutical approaches to improve patient management. Although discordant expression of the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2) in breast cancer is a known dilemma for appropriate patient management, traditional tumor sampling is often difficult or impractical. While 2-deoxy-2[¹⁸F]fluoro-D-glucose (¹⁸F-FDG)-positron emission tomography (PET) is an option to detect subclinical metastases, it does not provide phenotype information. Radiolabeled antibodies are able to specifically target expressed cell surface receptors. However, their long circulating half-lives (days) require labeling with long-lived isotopes, such as ⁸⁹Zr, in order t

SUBMITTER: Paquette M 

PROVIDER: S-EPMC7334319 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature